Does asthma-bronchiectasis overlap syndrome (ABOS) really exist?

Abstract

Objective

To analyze the relationship between asthma and bronchiectasis, as well as the necessary conditions that this connection must meet for this group of patients to be considered a special phenotype.

Data sources

We performed a PubMed search using the MeSH terms “asthma” and “bronchiectasis.” The literature research was limited to clinical trials, meta-analyses, randomized controlled trials, cohort studies, and systematic reviews, involving adult patients, published until November 30th, 2022.

Study selections

Selected papers were initially evaluated by the Authors, to assess their eligibility in contributing to the statements.

Results

The prevalence of bronchiectasis is higher than expected in patients with asthma, particularly in those with more severe disease, and in some patients, between 1.4% and 7% of them, asthma alone could be the cause of bronchiectasis. Both diseases share etiopathogenic mechanisms, such as neutrophilic and eosinophilic inflammation, altered airway microbiota, mucus hypersecretion, allergen sensitization, immune dysfunction, altered microRNA, dysfunctional neutrophilic activity, and variants of the HLA system. Besides that, they also share comorbidities, such as gastroesophageal reflux disease and psychiatric illnesses. The clinical presentation of asthma is very similar to patients with bronchiectasis, which could cause mistakes with diagnoses and delays in being prescribed the correct treatment. The coexistence of asthma and bronchiectasis also poses difficulties for the therapeutic focus.

Conclusions

The evidence available seems to support that the asthma-bronchiectasis phenotype really exists although longitudinal studies which consistently demonstrate that asthma is the cause of bronchiectasis are still lacking.

Keywords:

• Asthma
• bronchiectasis
• overlap
• eosinophils
• exacerbation
• comorbidities
• prognosis

Disclosure statement

Francisco-Javier Gonzalez-Barcala has received research grants or speaking or advisory fees, or economic aid to attend congresses from ALK, Astra-Zeneca, Bial, Boehringer-Ingelheim, Chiesi, Gebro Pharma, GlaxoSmithKline, Laboratorios Esteve, Menarini, Mundipharma, Novartis, Rovi, Roxall, Sanofi, Stallergenes-Greer, and Teva.

Angelica Tiotiu, Miguel-Angel Martinez-Garcia, Paula Mendez-Brea, and Iria Roibas-Veiga declare that they have no conflicts of interest related to this article.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.